Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

8296	Companies
114905	Keywords
55332	Articles
62461	Press releases

Home
Companies
Biophytis

BRIEF

published on 09/30/2024 at 23:05, 1 month 20 days ago

Biophytis Reports First-Half Financial Results and Updates on Business Activities

Financial Results Biophytis Clinical Trials Obesity Treatment Partnerships
PRESS RELEASE

published on 09/30/2024 at 23:00, 1 month 20 days ago

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
Biophytis publishes first-half financial results and business activities update, including launch of obesity program and licensing agreement with Blanver for Latin America, with a focus on key achievements and financial highlights

Financial Results Biophytis Licensing Agreement Business Activities Obesity Program
REGULATED PRESS RELEASE

published on 09/30/2024 at 23:00, 1 month 20 days ago

Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
Biophytis publishes first-half financial results and updates on business activities, highlighting key achievements including launch of OBA program for obesity with BIO101 and exclusive licensing agreement with Blanver for Latin America

Financial Results Biophytis Latin America BIO101 OBA Program
BRIEF

published on 07/22/2024 at 08:17, 3 months 30 days ago

Biophytis Enters Asia Market with Strategic Partnerships

Biophytis Pharmaceutical Partnerships Market Expansion Asia
PRESS RELEASE

published on 07/22/2024 at 08:12, 3 months 30 days ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis signs partnership contracts with local agents in Asia to accelerate deployment of BIO101 drug candidate, targeting age-related diseases in key markets like Japan and China

Biophytis Partnership Asia Age-related Diseases BIO101
BRIEF

published on 07/22/2024 at 07:05, 3 months 30 days ago

Biophytis Signs Contracts with Local Agents in Asia

Biotechnology Pharmaceutical Partnerships Age-related Diseases Asia Market
REGULATED PRESS RELEASE

published on 07/22/2024 at 07:00, 3 months 30 days ago

Biophytis deploys its partnership strategy and signs two contracts with local agents in Asia
Biophytis implements partnership strategy in Asia with new contracts to advance drug candidate BIO101 in Japan, South Korea, China, and Southeast Asia

Biophytis Asia Contracts Partnership Strategy Drug Candidate BIO101
BRIEF

published on 07/11/2024 at 08:18, 4 months 10 days ago

Biophytis Obtains IND Approval from FDA for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Clinical Trial BIO101 Obesity Study
PRESS RELEASE

published on 07/11/2024 at 08:13, 4 months 10 days ago

Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity
Biophytis receives FDA IND approval for phase 2 OBA study in obesity with BIO101 (20-hydroxyecdysone), focusing on muscle strength improvement. Study led by renowned expert Marc-André Cornier

FDA Biophytis Obesity IND Approval OBA Study
BRIEF

published on 07/11/2024 at 07:06, 4 months 10 days ago

Biophytis Receives FDA IND Approval for Phase 2 Obesity Study

Biophytis FDA Approval Phase 2 Study BIO101 Obesity

Accesswire

Published on 11/21/2024 at 13:30, 24 minutes ago

AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 13:30, 24 minutes ago

Datametrex Secures Additional P.O. Approx $250K for IT Services
Published on 11/21/2024 at 13:00, 54 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 54 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 54 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 39 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 1 hour 19 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 39 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 47 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 54 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 56 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 34 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 9 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 9 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE